No material surprise vs expectations — the stock will trade on Phase 3 enrollment updates and BIM-DRS FIH trial initiation in H2 2026. Monitor for any enrollment delays or safety signals in the ongoing registrational trials.
Price Chart
Executive Summary
SpyGlass Pharma reported Q1 2026 net loss of $13.8M ($-0.69/share), in line with the $-0.67 consensus estimate. The company highlighted $251M cash runway through 2028 and on-track Phase 3 enrollment for its BIM-IOL System, with BIM-DRS FIH trial expected in H2 2026. This is a pre-revenue clinical-stage biotech filing with no revenue to report — the focus is on pipeline execution and cash position.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $13.8M, or ($0.69) per basic/diluted share, vs consensus estimate of ($0.67)
- Cash, cash equivalents and short-term investments of $251.0M as of March 31, 2026, expected to fund operations through 2028
- Phase 3 trials (SGP-005 and SGP-006) enrollment on track with completion expected in 2027
- BIM-DRS first-in-human trial on track to start in H2 2026
- No revenue reported — pre-revenue clinical-stage company
- R&D expenses $8.5M (up from $6.1M YoY); G&A expenses $6.9M (up from $1.4M YoY) due to clinical hiring and public company costs
- IPO in February 2026 raised $172.5M in gross proceeds
Financial Impact
Net loss of $13.8M in Q1 2026, in line with consensus of ($0.67) per share; cash position $251M provides runway through 2028
Risk Factors
- Clinical trial enrollment delays or failure in Phase 3 BIM-IOL trials
- Cash burn rate may accelerate if trials expand or take longer than expected
- Regulatory risk — FDA approval not guaranteed for BIM-IOL System
- Competition from existing glaucoma treatments and other drug delivery platforms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001778922-26-000033 |
| Document: sgp-20260514.htm | 0001778922-26-000033 |
| Document: 0001778922-26-000033-index-headers.html | 0001778922-26-000033 |
| Document: 0001778922-26-000033-index.html | 0001778922-26-000033 |
| Document: 0001778922-26-000033.txt | 0001778922-26-000033 |
| 8-K Data (Synthetic) | 0001778922-26-000033 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 14, 2026 20w ago | 8-K | $23.21 $24.85 | ▲ +7.07% | ▲ +2.55% | $25.70 (+10.73%) |
Mar 26, 2026 27w ago | Press Release | $22.61 $19.75 | ▼ −12.65% | ▼ −28.72% | $25.70 (+13.67%) |
Mar 9, 2026 29w ago | Press Release | $27.12 $18.36 | ▼ −32.30% | ▼ −44.29% | $25.70 (−5.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access